Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Switching to SC zilucoplan from IV complement component 5 inhibitors in gMG: A Phase 3b, open-label study

    Miriam Freimer, Urvi Desai, Raghav Govindarajan et al.  July 05, 2025
    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Brivaracetam effectiveness and patient-reported outcomes in clinical practice: data from a 12-month prospective, observational study in the United States

    Hina Dave, Michael R Sperling, Hamada Hamid Altalib et al.  July 03, 2025
    phase 4/RWE
    Generalized Myasthenia Gravis
    View

    Incidence and Prevalence of Juvenile Myasthenia Gravis in the United States Between 2010 and 2020: Analysis of Two Claims Databases

    Jiachen Zhou, Anna Kuba, Sigrid Nilius et al.  June 01, 2025
    phase 4/RWE
    Generalized Myasthenia Gravis
    View

    High‑Dose Steroids, Treatment Escalation, and Healthcare Burden in Myasthenia Gravis: A US Claims‑Based Cohort Study

    Mar Pujades-Rodríguez, Adam Jedrzejczyk, Jiachen Zhou et al.  June 01, 2025
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis

    Channa Hewamadduma, Miriam Freimer, Angela Genge et al.  June 01, 2025
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study

    Kimiaki Utsugisawa, Masayuki Masuda, Babak Boroojerdi et al.  May 16, 2025
    phase 4/RWE
    Generalized Myasthenia Gravis
    View

    Risk of exacerbation and level of healthcare resource utilization in myasthenia 

    Angela Ting, Minjee Park, Oshin Sangha et al.  April 01, 2025
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication

    James F Howard Jr, Utsugisawa Kimiaki, M. Isabel Leite et al.  April 01, 2025
    phase 3

    RYSTIGGO® (rozanolixizumab-noli)

    Generalized Myasthenia Gravis
    View

    Rozanolixizumab improved symptoms in people with generalised myasthenia gravis in the MycarinG clinical study: a Plain Language Summary of Publication

    Bril Vera, Utsugisawa Kimiaki, Vu Tuan et al.  April 01, 2025
    phase 3

    RYSTIGGO® (rozanolixizumab-noli)

    Generalized Myasthenia Gravis
    View

    Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open‑label extension MG0004 study

    Bril Vera, Drużdż Artur, Grosskreutz Julian et al.  March 19, 2025